Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.77 |
| ▸ | TP53 | P04637 | 1/20 | 0.77 |
| ▸ | SLC29A1 | Q99808 | 15/20 | 0.71 |
| ▸ | STAT6 | P42226 | 2/20 | 0.69 |
| ▸ | DPP4 | P27487 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.69 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.69 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.69 |
| ▸ | GAPDH | P04406 | 1/20 | 0.69 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.69 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.69 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.69 |
| ▸ | PI4KA | P42356 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.69 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.69 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL672036 | 1.00 | SMN1; SMN2 (0.77) | SMN1; SMN2TP53SLC29A1STAT6DPP4 | |
| SCHEMBL7134319 | 1.00 | SMN1; SMN2 (0.77) | SMN1; SMN2TP53SLC29A1STAT6DPP4 | |
| SCHEMBL30089484 | 1.00 | SMN1; SMN2 (0.77) | SMN1; SMN2TP53SLC29A1STAT6DPP4 | |
| SCHEMBL19488384 | 1.00 | SMN1; SMN2 (0.77) | SMN1; SMN2TP53SLC29A1STAT6DPP4 | |
| SCHEMBL240981 | 1.00 | SMN1; SMN2 (0.77) | SMN1; SMN2TP53SLC29A1STAT6DPP4 | |
| SCHEMBL26294910 | 0.91 | SMN1; SMN2 (0.67) | SMN1; SMN2TP53SLC29A1STAT6DPP4 | |
| SCHEMBL8500982 | 0.90 | SLC29A1 (0.78) | SMN1; SMN2SLC29A1STAT6DPP4MEN1 | |
| SCHEMBL2580672 | 0.90 | SMN1; SMN2 (0.72) | SMN1; SMN2TP53SLC29A1STAT6DPP4 | |
| SCHEMBL9350374 | 0.89 | SLC29A1 (0.74) | SMN1; SMN2SLC29A1STAT6DPP4MEN1 | |
| SCHEMBL9347373 | 0.89 | SLC29A1 (0.74) | SMN1; SMN2SLC29A1STAT6DPP4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 773 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119619828-A | Instrument capable of realizing excitation test of synchronous motor in explosion-proof area | 中国石油天然气股份有限公司 | 2025-03-14 | — | — | CN | claimed |
| WO-2024182811-A1 | COMPOSITIONS AND METHODS FOR TREATING UTERINE LEIOMYOMAS | UNIVERSITY OF SOUTH FLORIDA (US) | 2024-09-06 | — | — | WO | claimed |
| US-20240024243-A1 | Fine Dry Particulate Adenosine Compositions and Topical Formulations Including the Same | LABORATORY SKIN CARE, INC. | 2024-01-25 | — | — | US | claimed |
| US-20230346820-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | THE SCRIPPS RESEARCH INSTITUTE | 2023-11-02 | — | — | US | claimed |
| WO-2022232518-A1 | CALXININ COMPOSITIONS AND METHOD FOR TREATING VIRAL INFECTIONS | UNM RAINFOREST INNOVATIONS (US) | 2022-11-03 | — | — | WO | claimed |
| US-20220273689-A1 | POTENTIATION OF ANTIVIRAL NUCLEOBASES AS RNA VIRUS THERAPY | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2022-09-01 | — | — | US | claimed |
| US-20220002737-A1 | ARTIFICIAL NUCLEIC ACID MOLECULES FOR IMPROVED PROTEIN EXPRESSION | CUREVAC AG (DE) | 2022-01-06 | — | — | US | claimed |
| US-20210379087-A1 | COMPOSITIONS FOR THE ELIMINATION OF SENESCENT CELLS | MEDIZINISCHE UNIVERSITÄT WIEN (AT) | 2021-12-09 | — | — | US | claimed |
| CN-113347969-A | Composition for eliminating senescent cells | 维也纳自然资源与生命科学大学 | 2021-09-03 | — | — | CN | claimed |
| US-11021497-B2 | Compositions and methods for synthesis of phosphorylated molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-06-01 | — | — | US | claimed |
| US-20030008841-A1 | Anti-HCV nucleoside derivatives | F. HOFFMAN-LA ROCHE, A SWISS COMPANY (CH) | 2003-01-09 | — | — | US | claimed |
| WO-2002045720-A1 | TREATMENT OF CANCER BY REDUCTION OF INTRACELLULAR ENERGY AND PYRIMIDINES | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2002-06-13 | — | — | WO | claimed |
| US-20020044919-A1 | Combinations and methods for treating neoplasms | YU, BAOFA | 2002-04-18 | — | — | US | claimed |
| US-6355623-B2 | DETERMINING THE LEVEL OF 6-THIOGUANINE METABOLITE WHEREIN A LEVEL OF 6-THIOGUANINE LESS THAN ABOUT 230 PMOL PER 8 X 108 RED BLOOD CELLS INDICATES A DRUG INCREASE; A LEVEL OF 400PMOL INDICATES A DECREASE; NONTOXIC | HOPITAL-SAINTE-JUSTINE (CA) | 2002-03-12 | — | — | US | claimed |
| EP-1171138-A2 | USE OF 6-METHYLMERCAPTOPURINE RIBOSIDE IN OPHTHALMOLOGIC COMPOSITIONS | Zoppetti, Giorgio (IT) | 2002-01-16 | — | — | EP | claimed |
| WO-2001052868-A1 | COMBINATIONS FOR TREATING NEOPLASMS | YU BAOFA (US) | 2001-07-26 | — | — | WO | claimed |
| WO-2000061122-A2 | USE OF 6-METHYLMERCAPTOPURINE RIBOSIDE IN OPHTHALMOLOGIC COMPOSITIONS | ZOPPETTI GIORGIO (IT) | 2000-10-19 | — | — | WO | claimed |
| EP-0831855-A1 | NUCLEOTIDE ANALOGUES FOR TOPICAL TREATMENT OF PROLIFERATIVE DISEASE OF THE SKIN | HOSTETLER, Karl Y. (US) | 1998-04-01 | — | — | EP | claimed |
| WO-1996040166-A1 | NUCLEOTIDE ANALOGUES FOR TOPICAL TREATMENT OF PROLIFERATIVE DISEASE OF THE SKIN | HOSTETLER KARL Y (US) | 1996-12-19 | — | — | WO | claimed |
| US-4088756-A | TREATING PSORIASIS, DERMATITIS WITH ADRENERGIC AGENTS AND HYPOGLYCEMIC AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1978-05-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220273689-A1 | POTENTIATION OF ANTIVIRAL NUCLEOBASES AS RNA VIRUS THERAPY | NSUN3, NSUN2, RNMT | SMN1; SMN2 817/4885TP53 1942/4885SLC29A1 17/4885 |
| US-20030008841-A1 | Anti-HCV nucleoside derivatives | PNP, HAVCR2, NUDT14 | SMN1; SMN2 4281/4885TP53 3695/4885SLC29A1 18/4885 |
| US-20220002737-A1 | ARTIFICIAL NUCLEIC ACID MOLECULES FOR IMPROVED PROTEIN EXPRESSION | CPSF6, CPSF1, RNMT | SMN1; SMN2 2664/4885TP53 237/4885SLC29A1 1623/4885 |
| US-11021497-B2 | Compositions and methods for synthesis of phosphorylated molecules | PIK3CA, CHAMP1, TYMP | SMN1; SMN2 3259/4885TP53 1059/4885SLC29A1 498/4885 |
| US-20230346820-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | ACE2, SARS1, ACE | SMN1; SMN2 2055/4885TP53 2487/4885SLC29A1 3931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.